CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Amazon Explores AI Content Marketplace With Media Publishers 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
TUSTIN, Calif., April 09, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the International Pharmaceutical Expo (INTERPHEX) 2018. The company’s activities will include participation in a conference panel focused on biologics outsourcing, as well as delivering a presentation on single-use manufacturing of biopharmaceuticals. INTERPHEX 2018 is being held April 17-19, 2018 at the Javits Center in New York, NY.
Details of Avid’s activities at INTERPHEX 2018 are as follows:
- Roger Lias, Ph.D., Avid’s president and chief executive officer, will participate on a conference panel titled, “Biologics Outsourcing.” The panel will take place from 2:15 – 3:00 p.m. Eastern on Wednesday, April 18th at booth #1053 within the CMO Theatre. The CMO Theatre is part of the conference’s dedicated CMO/CDMO Pavilion, which is being hosted by the Pharma and Biopharma Outsourcing Association (PBOA).
- Sun Ra Bullins, director of manufacturing at Avid, will make a presentation titled, “The Perks and Pitfalls of a Single-Use Biopharmaceutical Facility.” The presentation will take place from 11:30 a.m. – 12:15 p.m. Eastern on Tuesday, April 17th at booth #1053 within the CMO Theatre.
Sponsored by the Parenteral Drug Association (PDA), INTERPHEX brings over 11,000 global industry professionals and more than 630 industry leading suppliers together to “Learn it, Experience it, Procure it” through a unique combination of no cost technical conference, exhibits, demonstrations, roundtables, partnering opportunities and networking to leverage quality, efficiency and cost effectiveness in today’s ever-changing global market. For additional details on INTERPHEX 2018, please visit: http://www.interphex.com/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
